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Summary
Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 
receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this eﬀ ect. We investigated the safety 
and eﬃ  cacy of the combination of the IGF-1R antibody cixutumumab and the mTOR inhibitor temsirolimus in 
patients with chemotherapy-refractory bone and soft-tissue sarcomas according to IGF-1R expression by 
immunohistochemistry.
Methods We undertook a multicentre, open-label, phase 2 study in 19 cancer centres in the USA. Patients aged at least 
16 years with a histologically conﬁ rmed diagnosis of bone or soft-tissue sarcoma were allocated on the basis of IGF-1R 
expression by immunohistochemistry to one of three treatment groups: IGF-1R-positive soft-tissue sarcoma (group A), 
IGF-1R-positive bone sarcomas (group B), or IGF-1R-negative bone and soft-tissue sarcoma (group C). Patients 
received weekly treatment with cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous ﬂ at 
dose) in 6-week cycles. A Simon optimal two-stage design was used for every arm. The primary endpoint was 
progression-free survival (PFS) at 12 weeks by intention-to-treat analysis in the ﬁ rst 54 patients assigned to every 
treatment arm. Although patients still remain on treatment, this trial has completed enrolment and this represents 
the ﬁ nal analysis. This study is registered with ClinicalTrials.gov, number NCT01016015.
Findings Between Nov 18, 2009, and April 11, 2012, 388 patients were screened for IGF-1R expression and 54 were 
assigned to each arm. 17 of 54 patients in the IGF-1R-positive soft-tissue sarcoma group (31%; one-sided 95% CI 
lower bound 21%; two-sided 90% CI 21–43), 19 of 54 in IGF-1R-positive bone sarcoma group (35%; one-sided 95% CI 
lower bound 24%; two-sided 90% CI 24–47), and 21 of 54 in the IGF-1R-negative group (39%, one-sided 95% CI lower 
bound 28%; two-sided 90% CI 28–51) were progression free at 12 weeks. On April 6, 2011, the protocol was amended 
to include three additional patients in the IGF-1R-positive soft-tissue sarcoma group (total of 57 patients) and nine 
more in the IGF-1R-negative group (total of 63 patients). There were 2546 adverse events reported during the study, 
214 (8%) of which were grade 3–4. The most common grade 3–4 toxicities in the 174 treated patients were anaemia in 
16 (9%) patients, hyperglycaemia in 18 (10%), hypophosphataemia in 16 (9%), lymphopenia in 25 (14%), oral mucositis 
in 19 (11%), and thrombocytopenia in 19 (11%). 
Interpretation The combination of cixutumumab and temsirolimus shows clinical activity in patients with sarcoma 
and forms a basis for future trials. However, IGF-1R expression by immunohistochemistry is not predictive of clinical 
outcome after treatment with this combination. 
Funding National Cancer Institute and CycleforSurvival Fund, Memorial Sloan-Kettering Cancer Center.
Introduction
About 13 000 cases of soft-tissue and bone sarcoma are 
diagnosed annually in the USA.1 The median survival 
from diagnosis for patients with metastatic disease is 
about 10–18 months.2 In view of the toxicity and limited 
eﬃ  cacy of chemotherapy, patients with advanced and 
metastatic disease are appropriate candidates for 
investigational treatments. Insulin-like growth factor-1 
(IGF-1), IGF-2, and IGF-binding protein (IGF-BP) are 
expressed in various sarcoma subtypes, which suggests 
that IGF-1 receptor (IGF-1R) inhibition might be 
applicable in sarcomas.3 IGF-1R is activated by the growth 
factor ligands IGF-1 and IGF-2, resulting in receptor 
autophosphorylation, which leads to the activation 
of many signalling cascades, including the 
PI3K–Akt–mTOR pathway. Several lines of evidence 
have suggested that IGF-1R signalling is crucial to the 
biological changes in Ewing’s sarcoma and that targeting 
IGF-1R can inhibit tumour growth.4–8 However, in two 
large phase 2 trials in Ewing’s sarcoma, treatment with 
IGF-1R-targeting monoclonal antibodies, R1507 and 
ﬁ gitumumab, resulted in overall response rates of only 
10% and 14% and median progression-free survival (PFS) 
of 1·3 and 1·9 months, respectively.9,10
Combined inhibition of both IGF-1R and mTOR 
signalling represents a novel approach for treatment of 
sarcoma.11,12 Blockade of mTOR alone paradoxically ac-
tivates Akt.13 This ﬁ nding might explain the dis appointing 
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single-drug activity with mTOR inhibitors, such as 
temsirolimus, in patients with soft-tissue sar coma.14 
However, IGF-1R inhibition suppresses mTOR-induced 
Akt activation and sensitises tumour cells to mTOR 
inhibitors.13 Pretreatment of rhabdomyosarcoma cell lines 
with the IGF-1R antibody h7C10 resulted in blockade of 
rapamycin-induced Akt activation and in an enhanced 
antiproliferative eﬀ ect compared with either drug alone.12 
The IGF-1R antibody R1507 similarly enhanced the eﬀ ect 
of rapamycin by downregulating IGF-1R and blocking the 
reactivation of phosphorylated Akt (p-Akt) in a broad range 
of sarcoma cell lines.15 For sarcoma cell lines in which 
there was no IGF-1R expression, the combination of R1507 
and rapamycin was ineﬀ ective.15 Based on such data, 
phase 1 studies of the combination of IGF-1R and mTOR 
inhibitors in sarcoma have been undertaken.16,17 The fully 
humanised IgG1-monoclonal-antibody-targeting IGF-1R 
cixutumumab can be combined safely with the mTOR 
inhibitor temsirolimus at respective doses of 6 mg/kg and 
25 mg (ﬂ at dose) weekly.16 We therefore initiated a phase 2 
trial of cixutumumab and temsirolimus in bone and soft-
tissue sarcoma with stratiﬁ cation according to IGF-1R 
status. We hypothesised that IGF-1R expression by the 
tumour would be crucial to identify the clinical beneﬁ t of 
this drug combination and would be independent of 
histological subtype. Because response to IGF-1R antibody 
treatment on the basis of histological subtype alone has 
been scarce, we believed that upfront stratiﬁ cation by 
IGF-1R expression would result in an improved clinical 
beneﬁ t. Therefore, rather than stratify by histological 
subtype, we assessed clinical beneﬁ t according to IGF-1R 
expression by immuno histochemistry.
Methods
Patients
We undertook a multicentre, open-label, phase 2, non-
randomised trial in 19 cancer centres in the USA. Patients 
aged at least 16 years were eligible if they had an Eastern 
Cooperative Oncology Group performance status of 
0 or 1, histologically or cytologically conﬁ rmed sarcoma of 
soft tissue or bone, and measurable metastatic or locally 
advanced disease by Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.1, and if they had received at least one 
but not more than four previous treatments and had 
adequate organ function (deﬁ ned by a normal complete 
blood count [absolute neutrophil count ≥1·5 × 10⁹/L, 
platelet count ≥100 × 10⁹/L], liver function tests [total 
bilirubin ≤1·5 × institutional upper limit of normal [ULN] 
and aspartate aminotransferase and alanine amino-
transferase ≤3 × ULN], and renal function [serum 
creatinine ≤1·5 × ULN). Patients with hyper glycaemia, 
deﬁ ned as fasting serum glucose above 6·66 mmol/L, or 
those already on oral antidiabetic or insulin treatment 
were excluded from the study, as were those who received 
previous IGF-1R or mTOR inhibitors.
The study was undertaken in accordance with the 
Declaration of Helsinki. All patients provided written 
informed consent before enrolment after being informed 
about the purpose and the investigational nature of the 
study. The institutional review boards of all participating 
centres reviewed and approved the protocol.
Procedures
All patients had IGF-1R testing on archival tissue by 
immunohistochemistry at Memorial Sloan-Kettering 
Cancer Center (MSKCC; New York, NY, USA). Im muno-
histochemistry was done on 4-μm formalin-ﬁ xed paraﬃ  n 
embedded slides using pre-diluted IGF-1R antibodies 
(Ventana, Ventana Medical Systems, Tucson, AZ, USA) 
according to published methods.18 The scoring for IGF-
1R expression was quantitated on a 0–3+ scale: 0–1+, no 
staining or faint or weak staining; 2+, moderate staining; 
and 3+, strong staining. Only staining of 2+ to 3+ 
(cytoplasmic or membrane or both) was deemed positive. 
Scoring for IGF-1R expression was done by central 
pathology review (Cristina Antonescu, MSKCC) so as to 
minimise the inter-patient variability with immuno-
histochemistry.
Patients were assigned to one of three groups: those in 
group A had IGF-1R-positive sarcomas of soft tissue; 
those in group B had IGF-1R-positive sarcomas of bone; 
and those in group C had IGF-1R-negative sarcomas of 
bone and soft tissue. All patients received weekly 
treatment with cixutumumab (6 mg/kg intravenous) 
over 1 h followed 1 h later (30 min if the ﬁ rst two doses 
were tolerated) by temsirolimus (25 mg intravenous) in 
6-week cycles.
If grade 3 or 4 neutropenia or thrombocytopenia 
occurred, temsirolimus and cixutumumab were re-
spectively reduced by one (20 mg and 5 mg/kg) or two 
(15 mg and 4 mg/kg) dose levels. For hyperglycaemia of 
grade 1 toxicity or greater, oral antidiabetic treatment or 
insulin was started. For symptomatic grade 3 or any grade 4 
hyperglycaemia, cixutumumab was reduced by one or two 
dose levels. For any grade 1 hepatic toxicity (bilirubin, 
alanine aminotransferase, or aspartate aminotransferase) 
the temsirolimus dose was reduced immediately by two 
dose levels (15 mg). Hyperlipidaemia was treated with 
medical management rather than by dose reduction. 
Patients were assessed weekly for adverse events.
Clinical and radiological (contrast CT or MRI of chest, 
abdomen, and pelvis) assessments were obtained every 
6 weeks. Plasma samples for measurement of IGF-1 and 
IGF-BP3 concentrations by ELISA assay (R&D Systems, 
Minneapolis, MN, USA) were taken before treatment 
and on weeks 3 and 7. Plasma measurements were a 
requirement at MSKCC but were optional at other sites.
All patients treated at MSKCC were required to 
undergo tumour biopsies before and after treatment 
unless deemed clinically inappropriate. Biopsies were 
ﬂ ash frozen in liquid nitrogen before treatment and 
between weeks 2 and 3 for assessment of total IGF-1R, 
p-Akt, total Akt, phosphorylated S6 (p-S6), and total S6 by 
western blots according to standard techniques.15 Equal 
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loading of protein was conﬁ rmed by tubulin and GAPDH 
staining, and relative protein expression was quantiﬁ ed 
by densitometry assessment with ImageJ. All primary 
antibodies were obtained from Cell Signaling (Boston, 
MA, USA). 
The primary endpoint was PFS at 12 weeks in the ﬁ rst 
54 patients assigned to each treatment group, as assessed 
by RECIST 1.1. Secondary endpoints were overall 
survival, overall disease response, and correlation of 
plasma bio markers with clinical outcome. A post-hoc 
analysis was done by histological subtypes on 
progression-free survival, overall survival, and response.
Statistical analysis
Based on historical controls, a PFS of over 40% at 
3 months was deemed acceptable for second-line 
treatment and a PFS of less than 20% was deemed 
unacceptable.19 We used a Simon optimal two-stage 
design for every arm such that the outcome of the study 
was assessed by the decision rule of the study design.20 In 
particular, in stage 1, 19 patients were to be accrued. If 
fewer than ﬁ ve patients (26%) were progression free at 
12 weeks, further accrual would cease and the combination 
therapy would be declared ineﬀ ective. If at least ﬁ ve 
patients in stage 1 were progression free then an 
additional 35 patients would be accrued in stage 2 for a 
total of 54 patients. If at least 16 patients were progression 
free at 12 weeks among the ﬁ rst 54  patients, the arm 
would be judged to have a positive result and the 
combination therapy would be worthy of further testing. 
This design had a power of 0·90 for establishing the 
treatment eﬀ ect for a population 12-week PFS proportion 
of 40% using a type I error of 0·05. The probability of 
stopping each arm of the study early was 67% if the 
population 12-week PFS proportion was 20%.
Analyses of eﬃ  cacy data were done for all patients who 
had received any study drug (intention-to-treat). For 
every arm, the proportion of patients remaining free of 
progression at 12 weeks was estimated and a one-sided 
95% CI and a two-sided 90% CI were calculated. Median 
event-free times for all treated patients were estimated 
by the Kaplan–Meier method with a two-sided 95% CI 
and were compared between groups by the log-rank test 
with a two-sided p  value. Correlation of plasma 
biomarkers for IGF-1 and IGF-BP3 to PFS at 12 weeks 
was examined by the Wilcoxon rank sum test with a two-
sided p value for absolute levels at baseline, week 3, or 
week 7 and for change of levels at week 3 or week 7 from 
baseline. R software (version 2.14.2) was used for all 
statistical analyses. 
Role of the funding source
The sponsor of the study (National Cancer Institute) was 
involved in study design, data collection, and the 
decision to submit for publication in conjunction with 
the authors. The study sponsor had no role in data 
analysis, data interpretation, or writing of the report. 
Total IGF-1R 
positive
IGF-1R 
negative
Chondrosarcoma 38 20 (53%) 18 (47%)
Chordoma 6 1 (17%) 5 (83%)
Clear-cell tumour 6 5 (83%) 1 (17%)
Ewing’s sarcoma 61 33 (54%) 28 (46%)
Gastrointestinal stromal tumour 12 3 (25%) 9 (75%)
Leiomyosarcoma 45 26 (58%) 19 (42%)
Liposarcoma 11 5 (45%) 6 (55%)
Malignant peripheral nerve sheath tumour 11 9 (82%) 2 (18%)
Myxoﬁ brosarcoma 6 1 (17%) 5 (83%)
Osteosarcoma 52 33 (63%) 19 (37%)
Undiﬀ erentiated pleomorphic sarcoma 19 9 (47%) 10 (53%)
Rhabdomyosarcoma 10 7 (70%) 3 (30%)
Sarcoma, unspeciﬁ ed 14 7 (50%) 7 (50%)
Solitary ﬁ brous tumour 19 11 (58%) 8 (42%)
Spindle-cell tumour 17 8 (47%) 9 (53%)
Synovial sarcoma 18 14 (78%) 4 (22%)
Others 43 19 (44%) 24 (56%)
Data are number (%). IGF-1R=insulin-like growth factor-1 receptor. 
Table 1: Insulin-like growth factor-1 receptor status according to 
histological subtype in at least ﬁ ve patients for all screened patients 
Figure 1: Trial proﬁ le
IGF-1R=insulin-like growth factor-1 receptor. *Reasons for clinical screen failure: more than four treatments, brain 
metastases, abnormal laboratory values, congestive heart failure, or no measurable disease. †Other reasons 
included elected to undergo surgery, observation only, or radiation; unspeciﬁ ed reasons; or treatment was not 
covered by insurance.
54 assigned to IGF-1R-positive 
      soft-tissue sarcoma and 
      included in analysis of 
      primary endpoint
54 assigned to IGF-1R-positive 
       bone sarcoma and included 
       in analysis of primary 
       endpoint
3 included after 
   protocol 
   amendment 
57 included in all eﬃcacy and 
      safety analyses
54 included in all eﬃcacy and 
       safety analyses
15 gave plasma samples and 
      9 had tissue biopsies
23 gave plasma samples and 
      16 had tissue biopsies
54 assigned to IGF-1R-negative 
       soft-tissue and bone 
       sarcoma and included in 
       analysis of primary 
       endpoint
9 included after 
   protocol 
   amendment 
63 included in all eﬃcacy and 
       safety analyses
17 gave plasma samples and 
      7 had tissue biopsies
388 screened for eligibility
226 excluded
         68 study group closed to patient accrual 
         48 decline in performance status 
         32 pursued alternative therapy 
         32 ineligible*
         21 withdrew informed consent
          25 other†
162 eligible 
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GKS, L-XQ, VY, CB, AA, CRA, MC, MAD, SDV, ALH, 
and RGM had access to the raw data. The corresponding 
author (GKS) had full access to all the data in the study 
and had ﬁ nal responsibility for the decision to submit 
for publication.
Results
From Nov 18, 2009, to April 11, 2012, 388 patients were 
screened for IGF-1R expression by immunohisto-
chemistry. Of these, 211 (54%) were IGF-1R positive and 
177 (46%) were IGF-1R negative across many sarcoma 
subtypes (table 1). Patients were then enrolled into a 
treatment group at the discretion of the treating 
physicians until 54 patients had been enrolled in each 
group. All groups met the requirements for stage 1 before 
enrollment continued. The remainder of the screened 
patients were excluded because the study arm was closed 
to patient accrual or the patient did not meet protocol 
eligibility, had poor performance status, withdrew 
consent, elected to seek hospice or other treatments, or 
for other reasons (ﬁ gure 1). On April 6, 2011, the protocol 
was amended to include three additional patients in the 
IGF-1R-positive soft-tissue sarcoma group and nine in 
the IGF-1R-negative sarcoma group, giving a total of 
57 patients with IGF-1R-positive soft-tissue sarcoma 
(group A), 54 with IGF-1R-positive bone sar coma 
(group B), and 63 with IGF-1R-negative sarcoma 
(group C). This protocol amendment was made because 
of over enrolment into group A (patients who consented 
before enrolment was halted) and on the basis of 
promising results in ﬁ rst 54 patients in group C. Table 2 
shows the baseline demographics and patient charac-
teristics, including the most common histological sub-
types by IGF-1R status, for all treated patients. The mean 
number of previous systemic regimens was two (range 
one to four). 
After the ﬁ rst stage of enrolment, more than ﬁ ve 
patients in each group were progression free at 12 weeks. 
By intention-to-treat analysis, of the 54 patients in each 
group in the original cohort (ie, before the protocol 
amendment), 17 patients (31%; one-sided 95% CI lower 
bound 21%; two-sided 90% CI 21–43) in the IGF-1R-
positive soft-tissue sarcoma group, 19 patients (35%; one-
sided 95% CI lower bound 24%; two-sided 90% CI 24–47) 
in the IGF-1R-positive bone sarcoma group, and 
21 patients (39%; one-sided 95% CI lower bound 28%; 
two-sided 90% CI 28–51) in the IGF-1R-negative group 
were progression free at 12 weeks.
After the protocol amendment and inclusion of add-
itional patients, 17 of 57 patients (30%; one-sided 95% CI 
lower bound 20%; two-sided 90% CI 20–41) in the 
IGF-1R-positive soft-tissue sarcoma group and 26 of 63 
(41%; one-sided 95% CI lower bound 31%; two-sided 
90% CI 31–52) in the IGF-1R-negative group were pro-
gression free at 12 weeks. At the time of ﬁ nal analysis, the 
median follow-up of survivors was 18·6 months (range 
2·9–30·9). The median PFS by Kaplan–Meier estimates 
for all treated patients was 6·9 weeks (95% CI 5·9–12·0) 
for the IGF-1R-positive soft-tissue sarcoma group, 
10·6 weeks (6·0–15·3) for the IGF-1R-positive bone 
sarcoma group, and 11·6 weeks (9·3–17·9) for the 
IGF-1R-negative group (ﬁ gure 2A).
Based on 98 deaths and a median duration of follow-
up of 18·6 months (range 2·9–30·9), the median overall 
survival in all treated patients (n=174) was 18·9 months 
(95% CI 13·1 to not reached [NR]) for patients with 
IGF-1R-positive soft-tissue sarcoma, 14·2 months 
(7·6 to NR) for patients with IGF-1R-positive bone 
sarcoma, and 14·7 months (10·6 to NR) for patients 
with IGF-1R-negative sarcoma; ﬁ gure 2B). All deaths 
were due to disease progression.
Nine patients achieved a partial response: one (2%) of 
57 patients in the IGF-1R-positive soft-tissue sarcoma 
group, six (11%) of 54 patients in the IGF-1R-positive bone 
sarcoma group, and two (3%) of 63 patients in the IGF-1R-
negative group. There were no complete responses.
Analysis of plasma biomarkers in 55 patients (15 in the 
IGF-1R-positive soft-tissue sarcoma group, 23 in 
the IGF-1R-positive bone sarcoma group, and 17 in the 
IGF-1R-positive 
soft-tissue 
sarcoma (n=57)
IGF-1R-positive 
bone sarcoma 
(n=54)
IGF-1R-negative 
sarcoma (n=63)
Age (years) 50 (19–82) 38 (18–73) 55 (19–78)
Sex
Men 22 (39%) 32 (59%) 40 (63%)
Women 35 (61%) 22 (41%) 23 (37%)
ECOG PS
0 39 (68%) 30 (56%) 31 (49%)
1 18 (32%) 24 (44%) 32 (51%)
Previous treatments
1 14 (25%) 15 (28%) 18 (29%)
2 26 (46%) 17 (31%) 17 (27%)
3 14 (25%) 16 (30%) 24 (38%)
4 3 (5%) 6 (11%) 4 (6%)
Mean number of previous treatments 2·1 2·3 2·3
Most common histological subtype
Ewing’s sarcoma or primitive neuroectodermal 
embriogenic tumour
1 19 7
Osteosarcoma 0 18 6
Chondrosarcoma 0 11 6
Leiomyosarcoma 15 0 11
Undiﬀ erentiated pleomorphic sarcoma 6 3 10
Synovial sarcoma 8 0 3
Solitary ﬁ brous tumour 4 0 4
Malignant peripheral nerve sheath tumour 5 0 1
Well-diﬀ erentiated and dediﬀ erentiated 
liposarcoma
3 0 1
Gastrointestinal stromal tumour 2 0 2
Others 13 3 12
Data are mean (range), number (%), or number. ECOG PS=Eastern Co-operative Oncology Group performance status.
Table 2: Demographics and baseline characteristics
See Online for appendix
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IGF-1R-negative group) for IGF-1 and IGF-BP3 showed 
no correlation to PFS or overall survival (data not shown). 
All patients with disease progression at week 12 had 
signiﬁ cant increases in plasma biomarkers from baseline 
to weeks 3 or 7 (p<0·01 appendix).
32 patients (nine in the IGF-1R-positive soft-tissue 
sarcoma group, 16 in the IGF-1R-positive bone sarcoma 
group, and seven in the IGF-1R-negative group) at 
MSKCC had serial tumour biopsies undertaken before 
treatment and between weeks 2 and 3 of the ﬁ rst cycle of 
therapy and analysed by western blot. Although 
suppression of IGF-1R and inhibition of both p-S6 and 
p-Akt was noted in individual patients in all treatment 
arms, semi-quantitative analysis did not suggest any 
consistent association between the percent decrease in 
IGF-1R, p-S6, or p-Akt expression and clinical outcome 
(table 3). All patients in the immunohistochemistry-
deﬁ ned IGF-1R-negative group—in which IGF-1R was 
assessable by western blot (ﬁ ve of the seven)—were 
IGF-1R positive by western blot (table 3).
Of 2546 adverse events reported, 214 (8%) were 
grade 3–4. Grade 1–2 and 3–4 events that occurred in at 
least 5% of all patients treated are listed by stratiﬁ cation 
groups (table 4) and by histological subtype (appendix). 
The incidence of grade 3 and 4 events was similar 
between the three study arms. The most common 
grade 3–4 toxicities in the 174 patients were anaemia in 
16 (9%) patients, hyperglycaemia in 18 (10%) patients, 
hypo phosphataemia in 16 (9%) patients, lymphopenia in 
25 (14%) patients, oral mucositis in 19 (11%) patients, and 
thrombocytopenia in 19 (11%) patients. Although 
hyperglycaemia was noted in 119 (68%) of 174 patients, 
this was generally grade 1–2 and was well controlled. Of 
174 patients treated on the study, 83 (48%) experienced a 
serious adverse event; 43 (52%) of these patients had a 
serious adverse event reported as possibly, probably, or 
deﬁ nitely related to drug therapy. Among the serious 
adverse events for which a causal relation to drug therapy 
was suggested, only oral mucositis (12 [7%]) and 
thrombocytopenia (nine [5%]) occurred in at least 5% of 
174 patients treated. There were four (2%) deaths on 
study and all of these were attributable to disease 
progression. Except for one episode of hypoxia, there 
were no reports of pneumonitis.
91 (52%) of 174 patients needed either one (40 patients 
[23%]) or two (51 patients [29%]) dose reductions of 
temsirolimus. Of the 91 patients who needed one or 
more dose reductions, the most common causes were 
for thrombocytopenia (24 patients [26%]), oral mucositis 
(18 [20%]), or grade 1 or greater increases in 
aminotransferases (17 [19%]). 47 (27%) of 174 patients 
needed one (32 patients [18%]) or two (15 [9%]) dose 
reductions of cixutumumab. 16 (34%) of the 47 dose 
reductions were related to thrombocytopenia.
In a post-hoc analysis, we analysed median PFS, 
overall survival, and response according to histological 
subtype and IGF-1R status. The median PFS for the 
Figure 2: Kaplan–Meier curves for progression-free survival and overall survival
(A) Progression-free survival and (B) overall survival for all treated patients according to IGF-1R expression groups. 
Curves were truncated at 24 months for better presentation of the data. IGF-1R=insulin-like growth factor-1 receptor.
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most common histological subtypes were 7·5 weeks 
(95% CI 5·6–17·7) for Ewing’s sarcoma, 6·0 weeks 
(5·9–15·7) for osteosarcoma, 21·4 weeks (5·7–35·4) 
for chondrosarcoma, 11·4 weeks (6·3–15·3) for leio-
myo sarcoma, and 12·9 weeks (5·6–46·9) for 
undiﬀ erentiated pleomorphic sarcoma. For patients 
with osteosarcoma and leiomyosarcoma, IGF-1R status 
did not have an eﬀ ect on median PFS (ﬁ gure 3A and 
B). However, for Ewing’s sarcoma and chondrosarcoma, 
IGF-1R immuno histochemistry expression had a 
statistically signiﬁ cant eﬀ ect on median PFS (ﬁ gure 3C 
and D). Nine (82%) of 11 IGF-1R-positive chondro-
sarcomas were histologically grade 2 and 3 and ﬁ ve 
(56%) of these nine were dediﬀ erentiated. For patients 
with Ewing’s sarcoma, the median PFS was 
5·7 weeks (95% CI 4·3–11·9) for those with IGF-1R-
positive disease and and 17·7 weeks (9·0 to NR) for 
those with IGF-1R-negative disease (p=0·027, 
ﬁ gure 3C). For patients with chondro sarcoma, the 
median PFS was 23·0 weeks (11·0 to NR) for those 
with IGF-1R-positive disease and 8·1 weeks (3·0 to NR) 
for those with IGF-1R-negative disease (p=0·048, 
ﬁ gure 3D). For the eight patients with solitary ﬁ brous 
tumours, the median PFS for the four patients with 
IGF-1R-positive disease was 89·6 weeks (4·0 to NR) 
and 16·1 weeks (5·0 to NR) for those with IGF-1R-
negative disease, but this was not statistically 
signiﬁ cantly diﬀ erent (p=0·22). This analysis included 
two patients with IGF-1R-positive solitary ﬁ brous 
tumours who remained on study for 126 weeks and 
another who remains on study for 96 weeks. 
Median overall survival was 16·2 months (95% CI 
5·2 to NR) for Ewing’s sarcoma, 14·6 months (8·6 to NR) 
for leiomyosarcoma, not reached (7·6 to NR) for 
osteosarcoma, 13·6 months (10·6 to NR) for chondro-
sarcoma, 15·5 months (8·5 to NR) for undiﬀ erentiated 
pleomorphic sarcoma, and 18·9 months (11·9 to NR) for 
others (ﬁ gure 3E). In a post-hoc analysis, patients with 
IGF-1R-negative Ewing’s sarcoma also had a numerical 
but not statistically signiﬁ cant (p=0·16) improvement in 
median overall survival (NR, 95% CI 16·2 to NR) when 
compared with those who were IGF-1R positive 
(14·0 months, 4·6 to NR). 
Figure 4 shows the waterfall plot for best RECIST 
response according to histology. Four of 27 (15%) patients 
with Ewing’s sarcoma, three of 24 (13%) with osteo-
sarcoma, one of 17 (6%) with chondrosarcoma, and 
one of eight (13%) with solitary ﬁ brous tumour 
(hemangiopericytoma) had partial responses. There were 
no complete responses. Of the four patients with a 
diagnosis of gastrointestinal stromal tumour, one 
(IGF-1R positive) had a 13% decrease in tumour size 
from baseline as measured by RECIST.
Discussion
We undertook a phase 2 study to assess the safety and 
eﬃ  cacy of an IGF-1R antibody and a mTOR inhibitor in 
combination therapy in bone and soft-tissue sarcomas 
based on IGF-1R immunohistochemistry status. Tox-
icities were consistent with those reported in the phase 1 
study of this combination.16 The primary endpoint of PFS 
at 12 weeks ranged from 31% in patients with IGF-1R-
positive soft-tissue sarcoma to 39% in patients with 
IGF-1R-negative sarcoma. Based on historical controls, 
a PFS in this range suggests that the combination of 
cixutumumab and temsirolimus is active in sarcoma.19  
12-week PFS is a widely accepted benchmark for 
p-Akt (% 
change from 
baseline)
p-S6 (% 
change from 
baseline)
IGF-1R (% 
change from 
baseline)
Best RECIST 
response
IGF-1R-positive soft-tissue sarcoma
1 –75% –66% –92% Stable disease
2 –20% NA –18% Stable disease
3 –33% NA –34% Stable disease
4 –50% –90% –60% Stable disease
5 –88% –60% –88% Progressive disease
6 –90% –99% –98% Progressive disease
7 +200% NA +171% Stable disease
8 0% –20% –40% Progressive disease
9 NA NA NA Progressive disease
IGF-1R-positive bone sarcoma
1 –80% –100% –92% Stable disease
2 +239% +207% –27% Partial response
3 –33% –97% –94% Stable disease
4 –50% –89% –65% Stable disease
5 –57% –97% –57% Stable disease
6 –64% +200% +111% Progressive disease
7 –88% –98% –98% Progressive disease
8 –91% –100% –97% Progressive disease
9 –91% –98% –99% Stable disease
10 –94% –97% –97% Stable disease
11 +200% NA +127% Progressive disease
12 NA NA NA Progressive disease
13 +236% –70% –40% Stable disease
14 NA NA NA Progressive disease
15 NA –97% –99% Stable disease
16 NA NA NA Progressive disease
IGF-1R-negative soft-tissue and bone sarcoma
1 +121% NA +117% Stable disease
2 –48% –77% –37% Stable disease
3 –86% NA –82% NA
4 –89% –73% –45% Progressive disease
5 NA NA NA Stable disease
6 +137% –73% –64% Stable disease
7 NA –97% NA Stable disease
Data are shown for each patient (numbered) according to their assigned group. 
p-Akt=phosphorylated Akt. p-S6=phosphorylated S6. IGF-1R=insulin-like growth 
factor-1 receptor. RECIST=Response Evaluation Criteria in Solid Tumors. NA=not 
assessable.
Table 3: Percent change from baseline in protein expression for p-Akt, 
p-S6, and IGF-1R, relative to best response
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IGF-1R-positive soft-tissue 
sarcoma (n=57)
IGF-1R-positive bone sarcoma 
(n=54)
IGF-1R-negative sarcoma 
(n=63)
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Abdominal pain 6 (11%) 2 (4%) 0 1 (2%) 9 (14%) 0
Activated partial thromboplastin time prolonged 4 (7%) 1 (2%) 5 (9%) 1 (2%) 8 (13%) 2 (3%)
Alanine aminotransferase increased 18 (32%) 0 19 (35%) 0 18 (29%) 1 (2%)
Alkaline phosphatase increased 16 (28%) 0 18 (33%) 1 (2%) 19 (30%) 1 (2%)
Allergic rhinitis 3 (5%) 0 2 (4%) 0 7 (11%) 0
Alopecia 6 (11%) 0 4 (7%) 0 5 (8%) 0
Anaemia 22 (39%) 7 (12%) 29 (54%) 4 (7%) 42 (67%) 5 (8%)
Anorexia 24 (42%) 0 17 (31%) 0 26 (41%) 1 (2%)
Anxiety 4 (7%) 0 3 (6%) 0 8 (13%) 0
Arthralgia 1 (2%) 0 5 (9%) 0 4 (6%) 0
Aspartate aminotransferase increased 17 (30%) 1 (2%) 14 (26%) 0 17 (27%) 1 (2%)
Back pain 10 (18%) 1 (2%) 6 (11%) 1 (2%) 14 (22%) 0
Bruising 3 (5%) 0 2 (4%) 0 4 (6%) 0
Chest wall pain 4 (7%) 0 4 (7%) 0 6 (10%) 0
Cholesterol high 4 (7%) 1 (2%) 3 (6%) 0 3 (5%) 0
Constipation 20 (35%) 0 18 (33%) 0 25 (40%) 0
Cough 12 (21%) 1 (2%) 11 (20%) 1 (2%) 20 (32%) 0
Creatine increased 13 (23%) 1 (2%) 16 (30%) 0 15 (24%) 0
Dehydration 6 (11%) 0 2 (4%) 1 (2%) 8 (13%) 1 (2%)
Depression 5 (9%) 0 8 (15%) 0 5 (8%) 0
Diarrhoea 18 (32%) 2 (4%) 14 (26%) 1 (2%) 26 (41%) 6 (10%)
Dizziness 4 (7%) 0 4 (7%) 0 5 (8%) 0
Dry mouth 3 (5%) 0 5 (9%) 0 8 (13%) 0
Dry skin 14 (25%) 0 11 (20%) 0 9 (14%) 0
Dysgeusia 9 (16%) 0 9 (17%) 0 18 (29%) 0
Dyspnoea 15 (26%) 0 11 (20%) 1 (2%) 19 (30%) 2 (3%)
Epistaxis 11 (19%) 0 9 (17%) 0 14 (22%) 0
Fatigue 30 (53%) 3 (5%) 35 (65%) 2 (4%) 43 (68%) 1 (2%)
Fever 11 (19%) 1 (2%) 6 (11%) 1 (2%) 10 (16%) 0
Flu-like symptoms 4 (7%) 0 1 (2%) 0 3 (5%) 0
Gastro-oesophageal reﬂ ux disease 2 (4%) 0 0 0 7 (11%) 0
Generalised muscle weakness 3 (5%) 0 1 (2%) 0 3 (5%) 0
Headache 11 (19%) 0 13 (24%) 0 15 (24%) 0
Hypercalcaemia 7 (12%) 0 4 (7%) 0 4 (6%) 0
Hyperglycaemia 28 (49%) 7 (12%) 35 (65%) 4 (7%) 38 (60%) 7 (11%)
Hyperkalaemia 2 (4%) 1 (2%) 1 (2%) 0 9 (14%) 0
Hypernatraemia 2 (4%) 1 (2%) 1 (2%) 0 8 (13%) 0
Hypertriglyceridaemia 19 (33%) 4 (7%) 24 (44%) 2 (4%) 26 (41%) 2 (3%)
Hypoalbuminaemia 15 (26%) 1 (2%) 13 (24%) 0 16 (25%) 0
Hypocalcaemia 10 (18%) 0 7 (13%) 1 (2%) 12 (19%) 2 (3%)
Hypoglycaemia 3 (5%) 0 4 (7%) 0 2 (3%) 0
Hypokalaemia 12 (21%) 2 (4%) 7 (13%) 1 (2%) 11 (17%) 1 (2%)
Hyponatraemia 10 (18%) 2 (4%) 14 (26%) 0 19 (30%) 2 (3%)
Hypophosphataemia 5 (9%) 5 (9%) 7 (13%) 4 (7%) 5 (8%) 7 (11%)
Hypotension 3 (5%) 0 1 (2%) 1 (2%) 3 (5%) 0
International normalised ratio increased 3 (5%) 1 (2%) 4 (7%) 0 3 (5%) 1 (2%)
Insomnia 3 (5%) 0 6 (11%) 0 11 (17%) 0
Leucopenia 23 (40%) 3 (5%) 24 (44%) 2 (4%) 28 (44%) 4 (6%)
Limb oedema 7 (12%) 0 3 (6%) 0 9 (14%) 1 (2%)
Lymphocytopenia 8 (14%) 9 (16%) 6 (11%) 7 (13%) 13 (21%) 9 (14%)
(Continues on next page)
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assessment of new drugs in sarcoma. It has been the 
primary endpoint of several clinical trials including the 
single-arm phase 2 study of pazopanib in sarcoma,21 a 
drug that is now approved by the US Food and Drug 
Administration for this disease. Additionally, the 
evidence of stable disease for at least 1 year in two patients 
with solitary ﬁ brous tumours and partial responses in 
patients with Ewing’s sarcoma, osteosarcoma, solitary 
ﬁ brous tumour, and chondro sarcoma would support an 
argument that these drugs could oﬀ er disease control to 
subsets of patients with sarcoma (panel). 
We hoped that IGF-1R expression by immuno-
histochemistry would be predictive of an improved 
outcome with therapy. The disease control noted in the 
IGF-1R-negative immunohistochemistry group was at 
least as good as that in the IGF-1R-positive groups. This 
inability to show an improved outcome across all 
tumour histological subtypes on the basis of IGF-1R 
expression does point out potential limitations to using 
IGF-1R immuno histo chemistry as a screening tool for 
an IGF-1R-directed treatment. This could be because of 
limited antibody sensitivity. Therefore, the inability to 
detect IGF-1R by immunohistochemistry in patients 
using the Ventana antibody, who were otherwise IGF-1R 
positive by western blot using the Cell Signaling 
antibody, suggests that the Ventana antibody might not 
be sensitive enough to detect the low levels of IGF-1R 
expression. By standardising our immunohisto-
chemistry assay and by having one sarcoma pathologist 
for central review of all the immunohistochemistry 
stained slides, we tried to avoid many of the pitfalls 
associated with immunohistochemistry staining. These 
pitfalls include broad inter-laboratory variability in 
performance of the assay, discrepancies between labora-
tories with high-volume versus low-volume throughput, 
use of diﬀ erent antibodies across sites, and deviations 
from recommended methods in the package insert 
leading to altered performance characteristics of the 
assays. Diﬀ erent cutoﬀ  points for classifying a positive 
result can also aﬀ ect interpretation of the data. In our 
 IGF-1R-positive soft-tissue 
sarcoma (n=57)
IGF-1R-positive bone sarcoma 
(n=54)
IGF-1R-negative sarcoma 
(n=63)
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
(Continued from previous page)
Musculoskeletal and connective tissue disorder— 
other
2 (4%) 0 1 (2%) 0 6 (10%) 0
Myalgia 8 (14%) 0 8 (15%) 0 7 (11%) 0
Nail infection 3 (5%) 0 0 0 5 (8%) 0
Nail ridging 2 (4%) 0 2 (4%) 0 4 (6%) 0
Nasal congestion 2 (4%) 0 6 (11%) 0 5 (8%) 0
Nausea 20 (35%) 0 20 (37%) 0 24 (38%) 0
Neutropenia 8 (14%) 2 (4%) 13 (24%) 5 (9%) 13 (21%) 4 (6%)
Non-cardiac chest pain 3 (5%) 0 3 (6%) 2 (4%) 2 (3%) 0
Oral mucositis 36 (63%) 5 (9%) 27 (50%) 9 (17%) 42 (67%) 5 (8%)
Pain 20 (35%) 2 (4%) 22 (41%) 1 (2%) 26 (41%) 0
Papulopustular rash 5 (9%) 1 (2%) 2 (4%) 0 2 (3%) 0
Paraesthesia 2 (4%) 0 2 (4%) 0 5 (8%) 0
Paronychia 4 (7%) 0 3 (6%) 0 3 (5%) 0
Peripheral sensory neuropathy 5 (9%) 0 7 (13%) 0 9 (14%) 0
Pruritus 11 (19%) 0 5 (9%) 0 12 (19%) 0
Rash acneiform 2 (4%) 0 13 (24%) 0 12 (19%) 0
Rash maculopapular 12 (21%) 2 (4%) 12 (22%) 0 16 (25%) 0
Sinusitis 2 (4%) 0 1 (2%) 0 5 (8%) 0
Skin infection 4 (7%) 0 3 (6%) 0 6 (10%) 0
Sore throat 6 (11%) 0 4 (7%) 0 6 (10%) 0
Upper respiratory infection 2 (4%) 0 2 (4%) 0 5 (8%) 0
Urinary tract infection 5 (9%) 2 (4%) 1 (2%) 1 (2%) 3 (5%) 1 (2%)
Thrombocytopenia 30 (53%) 3 (5%) 30 (56%) 7 (13%) 32 (51%) 9 (14%)
Vomiting 15 (26%) 1 (2%) 13 (24%) 0 14 (22%) 0
Weight loss 10 (18%) 0 9 (17%) 0 21 (33%) 1 (2%)
Total 712 75 675 62 945 77
Data are number (%).
Table 4: Adverse events of grade 1 or higher experienced by at least 5% of patients
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study we limited enrolment to tumour tissue that was 
2–3+ by immunohistochemistry. This stringent cutoﬀ  
might have excluded patients from the study who would 
have been otherwise IGF-1R positive. There are several 
pitfalls associated with western blotting, especially for 
the detection of phosphoproteins on tumour tissues, 
including the handling of the tissues, the time from 
tumour procurement to ﬂ ash freezing, the amount of 
tumour available for analysis, and the speciﬁ city of the 
antibodies used. In our study, to minimise several of 
these issues, we obtained tumour biopsies at only one 
site (MSKCC) and all samples were ﬂ ash frozen almost 
immediately upon biopsy within the interventional 
radiology suite. For the plasma correlates (IGF-1 and 
IGF-BP3 by ELISA), even though they were run at one 
site (MSKCC), they were obtained at multiple cancer 
centres, leaving us susceptible to some of the same 
issues mentioned previously for tumour procurement.
Although there was no overall eﬀ ect of IGF-1R 
expression by immunohistochemistry on outcome, 
a post-hoc analysis of IGF-1R immunohistochemistry 
according to speciﬁ c sarcoma subtypes did reveal that 
patients with Ewing’s sarcoma who were IGF-1R 
negative by immunohistochemistry had better median 
PFS than those who were IGF-1R positive. This ﬁ nding 
suggests that in Ewing’s sarcoma, with the present drug 
dosing (6 mg/kg), low concentrations of IGF-1 receptor 
might be more easily saturated than higher 
concentrations. Alter natively, Ewing’s sarcoma with low 
IGF-1R immuno histochemistry expression might have 
Figure 3: Kaplan–Meier curves for post-hoc analyses
Progression-free survival curves for (A) osteosarcoma, (B) leiomyosarcoma, (C) Ewing’s sarcoma, and (D) chondrosarcoma. (E) Overall survival curves by histological subtype. Survival curves were 
truncated at 24 months for better presentation of the data. IGF-1R=insulin-like growth factor-1 receptor. PNET=primitive neuroectodermal embryogenic tumour.
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less aggressive biological eﬀ ects. However, this 
suggestion is con founded by the fact that IGF-1R-
positive chondrosar comas still had a better median PFS 
over IGF-1R-negative chondrosarcomas. The higher 
incidence of high-grade and dediﬀ erentiated chondro-
sarcomas in the IGF-1R-positive group suggests that this 
better outcome was not because of less aggressive 
histological changes. These results, relative to IGF-1R 
status for speciﬁ c sarcoma histological changes, are 
based on small numbers and should still be considered 
exploratory.
Pappo and colleagues10 suggested that the moderate 
clinical beneﬁ t noted with the IGF-1R antibody R1507 
as a single drug in the treatment of Ewing’s sarcoma 
could have been because of under dosing of the drug.10 
Because the minimum dose of cixutumumab needed 
for inhibition of IGF-1R is unknown, the dose 
reductions needed for cixutumumab-related toxicity 
could have inﬂ uenced the outcome of the present study. 
The same issue applies to temsirolimus, for which we 
used a starting dose of 25 mg intravenous weekly. 
Although this dose will modulate p-S6, lower doses 
have not been assessed and whether lower doses will 
inhibit mTOR signalling is unknown. This point is 
particularly relevant to our study because over 50% of 
the patients needed a dose reduction of temsirolimus 
and this also could have had a negative eﬀ ect on the 
primary study outcome. Therefore, without additional 
historical data linking the pharmacology of these drugs 
with pharmaco dynamic changes, especially at low 
doses, identifying how these dose reductions within the 
trial aﬀ ected median PFS is diﬃ  cult. However, the 
western blots from our study conﬁ rmed pathway 
inhibition in some patients with downregulation of 
IGF-1R and inhibition of p-Akt and p-S6 in all arms of 
this study, particularly within the ﬁ rst cycle of therapy, 
suggesting a suﬃ  cient biological eﬀ ect to inhibit 
IGF-1R and mTOR signalling at the recommended 
phase 2 dose of cixutumumab and temsirolimus in the 
combination therapy. Despite evidence for target 
inhibition within the tumours, disease control was not 
achieved in many of these patients. One possibility is 
that there might be other receptor tyrosine kinases that 
are activated in sarcoma that need to be targeted in 
concert with mTOR to maximise p-Akt inhibition.15 
However, we do not know whether pathway inhibition 
was sustained beyond weeks 2–3 when the matched 
pair biopsies were obtained, especially at later times in 
the trial when dose reductions for toxicity were started. 
We were unsuccessful in obtaining tumour tissue at the 
time of disease progression, and so assessment of the 
exact mechanism for drug resistance and tumour 
progression is diﬃ  cult.
Median overall survival was over 14 months for all 
patients in the study. Comparison of data regarding 
single-drug IGF-1R targeting with other IGF-1R-mTOR 
combinations or even with best supportive care is 
diﬃ  cult. The only comparison that can be made is with 
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Figure 4: Waterfall plot of best change from baseline according to the most common histological subtypes
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patients with Ewing’s sarcoma. With R1507 alone in 
Ewing’s sarcoma, median PFS was 5·7 weeks, the 
RECIST response rate was 10%, and median overall 
survival was 7·6 months.10 In the phase 1, dose-
expansion phase of the trial of patients with Ewing’s 
sarcoma treated with cixutumumab and temsirolimus, 
there was a 29% response rate and a median overall 
survival of 12·6 months (median PFS not reported).16 
With cixutumumab and temsirolimus in the present 
trial, even though the median PFS for the whole group 
was 6·0 weeks, the response rate was 15% and the 
median overall survival was 16·2 months. Furthermore, 
an examination of patients with Ewing’s sarcoma by 
IGF-1R immunohistochemistry expression suggests 
that pa tients who were IGF-1R negative had a better 
median PFS than those who were IGF-1R positive. 
Additionally, although not statistically signiﬁ cant, in a 
post-hoc analysis, patients with IGF-1R-negative Ewing’s 
sarcoma also had a numerical improvement in median 
overall survival when compared with those who were 
IGF-1R positive. Collectively, these results suggest that 
the combination therapy should be explored in future 
clinical studies, especially for speciﬁ c sarcoma histo-
logical subtypes where IGF-1R immunohistochemistry 
status might have an eﬀ ect on clinical beneﬁ t and where 
signs of clinical response were noted (ie, Ewing’s 
sarcoma, chondrosarcoma, and solitary ﬁ brous tumour).
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